Ivonescimab shows 50.7% pathological complete response rate in Phase II perioperative non-small cell lung cancer study

In a Phase II trial, ivonescimab achieved a 50.7% pathological complete response (pCR) rate in patients with perioperative resectable non-small cell lung cancer (NSCLC) who received neoadjuvant ivonescimab plus chemotherapy and proceeded to surgery. This rate is significantly higher than the approximately 18% pCR rate seen in a comparable pembrolizumab trial, suggesting a potential new standard of care. The study also reported a 70.1% major pathological response rate and over 80% 12-month event-free survival.